| Literature DB >> 35280265 |
Thomas Hartwig Siebner1,2, Stefan Fuglsang3, Christopher Fugl Madelung1,4, Annemette Løkkegaard4,5, Flemming Bendtsen5,6, Jens Dahlgaard Hove1,2, Morten Damgaard3, Jan Lysgård Madsen3, Hartwig Roman Siebner1,4,5.
Abstract
Background: We have recently used phase-contrast magnetic resonance imaging (PC-MRI) to demonstrate an attenuated postprandial blood flow response in the superior mesenteric artery (SMA) in 23 medicated patients with Parkinson's disease (PD) compared to 23 age- and sex-matched healthy controls. Objective: To investigate in a sub-sample of the original cohort whether the observed blood flow response in SMA after oral food intake is related to a delay in gastric emptying.Entities:
Keywords: Parkinson's disease; gastric emptying; gastrointestinal dysfunction; non-motor symptoms; postprandial blood flow; scintigraphy
Year: 2022 PMID: 35280265 PMCID: PMC8910363 DOI: 10.3389/fneur.2022.828069
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Demographic and scintigraphic gastric emptying data from studies of patients with Parkinson's disease (PD) in comparison with healthy controls (HC) in the last 25 years.
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|
| HC (22) | 45 ± 3.5 | 56 ± 5 | ||||
| PD (15) | 62 ± 9 | 221 ± 202 | 2-4 | 8.8 ± 4.6 | ON with fluctuating symptoms (presence of “wearing-off and “delayed-on” phenomena) | |
| PD (15) | 64.8 ± 9.9 | 85 ± 31 | 1-4 | 4.0 ± 3.3 | ON without response | |
| HC (22) | 61.9 ± 6.1 | 43.4 ± 10.8 | ||||
|
| ||||||
| PD (29) | 61.5 ± 5.9 | 63.4 ± 28.8 | 1–2 | 3.6 ± 3.6 | 8 ON of which 2 with response fluctuations, 21 OFF (untreated) | |
| PD (22) | 65.1 ± 5.6 | 54.7 ± 25.5 | 2.5-3 | 7.1 ± 5.3 | 15 ON of which 11 with response fluctuations [presence of “wearing-off”, “delayed on”, “no on”, or “on/off” phenomena, 7 OFF (untreated)] | |
|
| ||||||
| PD (28) | 62.8 ± 5.6 | 59.5 ± 30.6 | - | - | OFF (untreated) | |
| PD (13) | 63.6 ± 6.6 | 49.3 ± 16.2 | - | - | ON with fluctuating symptoms | |
| PD (10) | 73.6 ± 25.8 | - | - | ON without response | ||
| HC (15) | 59.5 ± 9.7 | 38.4 ± 7.3 | ||||
| Familial PD | 59.0 ± 8.2 | 58 ± 25 | 1–3 | 8.4 ± 5.2 | ON | |
| Sporadic PD (35) | 60.5 ± 9.9 | 46 ± 25 | 2–4 | 7.1 ± 4.3 | ON | |
| HC (12) | 62 ± 8 | 75 ± 22 | ||||
| PD (12) | 64 ± 9 | 56 ± 22 | 1–3 | 5.3 | OFF (withdrawn from anti-parkinsonian medication for 12 h) | |
| HC (21) | 64.8 ± 1.8 | 100 ± 29 | ||||
| PD (21) | 64.2 ± 1.6 | 106 ± 42 | 1–2.5 | 6.3 ± 0.9 | 3 ON, 18 OFF (withdrawn from the morning dose of anti-parkinsonian medication) | |
| HC (17) | 65.4 ± 6.2 | 48.2 ± 16 | ||||
| PD (22) | 64.7 ± 7.1 | 50.6 ± 11 | 1–3 | 4.4 ± 4 | ON | |
Studies not including a control group or studies recruiting highly selected PD patients were excluded. n, Number of participants; SD, Standard deviation.
Presence of at least 2 affected individuals within 2–3 consecutive generations in a family.
Data are presented as mean ± SE.
Demographic data based on 32 PD patients and 26 healthy control subjects, respectively.
Missing data from Gjerløff et al. and Trahair et al. were obtained from the corresponding authors by Knudsen et al. (.
Demographic and clinical data of patients with Parkinson's disease (PD) and healthy controls.
|
|
|
| |
|---|---|---|---|
| Sex (male/female) | 11/4 | 9/6 | |
| Age (years) | 60.5 ± 9.4 | 64.6 ± 5.6 | 0.16 |
| Body mass index (kg/m2) | 25.8 ± 3.2 | 25.7 ± 3.6 | 0.96 |
| Levodopa equivalent dose (mg) | – | 599 ± 256 | |
| Disease duration (years) | – | 4 (2–6) | |
|
| |||
| Total NMS-Quest score | 0 (0–1) | 8 (4–15) | <0.0001 |
|
| |||
| AUC (% x hour) | 123 (91–151) | 120 (82–161) | 0.68 |
|
| |||
| Postprandial increase in BF (l/min) | 0.74 (0.49–0.95) | 0.43 (0.23–0.69) | 0.006 |
| Time to maximum (min) | 28.9 (22.7–37.9) | 30.3 (20.5–51.1) | 0.68 |
|
| |||
| Postprandial BG increase (mmol/l) | 2.2 (1.8–3.5) | 1.95 (1.3–3.4) | 0.08 |
| Time to maximum (min) | 58.5 (43.1–63.7) | 49.4 (38.6–63.3) | 0.33 |
Data given as mean ± SD or median (10% quantile.
marks preceding measurements based on the subjects (n = 14 PD patients and 12 healthy controls), who participated in serial MRI-based measurements of blood flow in the superior mesenteric artery (SMA) interrupted by interspersed blood glucose measurements (.
Figure 1Experimental procedures. Participants ingested a standardized radiolabeled test meal consisting of 80 g bread, 30 g jam and 120 g omelet, which was radiolabeled with 40 MBq 99mTc human albumin colloidal particles (Nanocoll), and 120 ml of water. Gastric emptying was assessed using static scintigraphy of the abdominal region for 2 minutes in both anterior and posterior projection in upright position at six timepoints following meal intake. h, hour; min, minutes.
Figure 2Gastric emptying in healthy control participants (HC) and patients with Parkinson's disease (PD). Individual gastric emptying of the radiolabeled standardized test meal shown as gastric retention at t = 0, 30, 60, 120, 180, and 240 min after meal intake with measurements connected using linear interpolation. Mean gastric retention and standard error of the two groups are visualized by fitting a Local Polynomial Regression (LOESS) function: Mean values, black curves; standard error, shaded areas. (h), hour.
Figure 3Boxplot of gastric emptying measurements in healthy controls (HC) and patients with Parkinson's disease (PD). Boxes represent the interquartile range with horizontal lines indicating the median of the gastric retention in each group at t = 0, 30, 60, 120, 180, and 240 min. Whiskers represent the smallest and the largest values within 1.5 times the 25 and 75th percentiles, respectively. Dots represent extreme outlier values (i.e., values above 1.5 times the interquartile range). (h), hour.
Correlations of clinical data patients with Parkinson's disease (PD) and healthy controls.
|
|
|
|
| |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| AUC vs. Blood flow increase | −0.113 | 0.58 | −0.074 | 0.82 | −0.328 | 0.25 |
| AUC vs. Blood flow time to maximum | 0.049 | 0.81 | −0.161 | 0.62 | 0.253 | 0.38 |
|
| ||||||
| AUC vs. Age | −0.12 | 0.53 | 0.106 | 0.71 | −0.217 | 0.44 |
| AUC vs. Blood glucose increase | −0.216 | 0.29 | −0.085 | 0.79 | −0.232 | 0.43 |
| AUC vs. Blood glucose time to maximum | −0.248 | 0.22 | −0.613 | 0.03* | −0.064 | 0.83 |
| AUC vs. NMS-Quest score | 0.17 | 0.37 | 0.338 | 0.22 | 0.57 | 0.03* |
| AUC vs. Disease duration | −0.104 | 0.71 | ||||
| AUC vs. LEDD | 0.229 | 0.41 | ||||
Correlations are expressed as Spearman's rank correlation coefficient (ρ = rho). Gastric emptying is expressed as area under the curve (AUC). LEDD, Levodopa equivalent daily dose; NMS-Quest, Non-Motor Symptoms Questionnaire.
Significant p-values are corrected for multiple comparisons based on Bonferroni correction. For primary variables an adjusted significance level of p < 0.0025 is applied, while for exploratory analyses significant p-values are adjusted to p < 0.0083 as the statistical threshold. Based on Bonferroni correction there is no significant p-value, while trend toward significance is expressed by “.